Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.
Dragonfly Therapeutics, Inc.的外部链接
US，MA，Waltham，02451
Dragonfly Therapeutics, Inc.转发了
Screening of our CEO Bill Haney's new movie documentary at #JPM25, featuring the wonderful Phil Sharp, Nobel Prize winning RNA & Splicing guru & Member of our SAB, and the Biotech Revolution (with many other impressive folks). Thank you to John Carrol Endpoints News for doing the Q&A (and being in the film!)
If you missed the first poster session, you can still make it to this evening's! One of our poster abstracts was selected for the top 100 #SITC24!
Dragonfly Therapeutics is presenting 2 posters, today, at the Society for #Immunotherapy of #Cancer (#SITC24) Annual Conference! Swing by during the poster session and learn more. https://lnkd.in/eYMqKnsZ
Proudly presenting our Phase 1/1b, First-in-Human, multi-part study of DF6215, an engineered IL-2Rα-active agonist for advanced solid tumors, in the Developmental Therapeutics-Immunotherapy poster session at American Society of Clinical Oncology (ASCO) with Benedito A. Carneiro, MD, MS, Brown University #ASCO24
Dragonfly is in Chicago! #ASCO24
We have entered into a clinical collaboration with Merck to evaluate DF9001, our EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors expressing EGFR. https://lnkd.in/eErs3u3n
We're super proud to be in the top 3 Best Biotech Startup Employers in the Boston area by @Forbes for 2024! 3000 privately-held Startup companies were evaluated on 3 primary criteria: company reputation, employee satisfaction and growth (each Startup must also have been started from scratch, founded between 2014 and 2021, headquartered in the U.S., and have more than 50 employees). https://lnkd.in/gic_9qPz
First Patient dosed in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 in solid tumors. This is the sixth TriNKET® and the eighth Dragonfly drug to enter into clinical trials! https://lnkd.in/dXibkKrc